Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

Recruiting now · Not applicable

Conditions studied: Alzheimer's Disease (AD)

In brief

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Key facts

Study ID

NCT07666113

Run by

Universitaire Ziekenhuizen KU Leuven

People needed

240

Starts

2026-05-26

Expected to finish

2038-04-01

Last updated by the study team

2026-06-24

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.

You may not qualify if…

• Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
• Concomitant medications that would interfere with cognitive assessments.
• A prior diagnosis of AD and related disorders or other neurodegenerative disease.

Where it is running

• UZ Leuven/KU Leuven — Leuven, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.